F605 in Alaska. Pick another state for the same tag.
Against expectation — 2025
Alaska cites F605 less often than its own record predicts
Versus expected share0.76×
0.76 times the national share — cited less often here than elsewhere.
Share of Alaska citations0.53%
Of every deficiency written in Alaska in 2025, this is the portion that was F605.
Alaska0.53%
National0.70%
Share of all citations that were F605.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Alaska surveyors wrote
F605 findings written in Alaska, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
D · No harm, potential for more than minimal, isolatedAugust 28, 2026
. Based on record review and interview, the facility failed to ensure 1 Resident (#5), out of 5 residents reviewed for unnecessary medications: 1) received a gradual dose reduction (GDR - a tapering of a dose to determine if symptoms or conditions could be managed by a lower dose, or if the dose or medication could be discontinued for an antipsychotic medication (a psychotropic medication primarily used to treat psychosis, including delusions, hallucinations, disorganized thinking or speech, and inappropriate behavior); or 2) had a documented clinical contraindication to attempt a GDR. This failed practice placed Resident #5 at risk for unnecessary antipsychotic medication use. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction